Rachana Bhattarai1, Hélène Carabin2, Jefferson V Proaño3, Jose Flores-Rivera4, Teresa Corona4, Ana Flisser5, Christine M Budke1. 1. Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA. 2. Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3. Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México DF, Mexico. 4. Clinical Laboratory of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, México DF, Mexico. 5. Facultad de Medicina, Universidad Nacional Autónoma de México, México DF, Mexico.
Abstract
OBJECTIVES: To estimate annual costs related to the diagnosis, treatment and productivity losses among patients with neurocysticercosis (NCC) receiving treatment at two referral hospitals, the Instituto Nacional de Neurologia y Neurocirugia (INNN) and the Hospital de Especialidades of the Instituto Mexicano del Seguro Social (HE-IMSS), in Mexico City from July 2007 to August 2008. METHODS: Information on presenting clinical manifestations, diagnostic tests, hospitalisations, surgical procedures and other treatments received by NCC outpatients was collected from medical charts, and supplemented by an individual questionnaire regarding productivity losses and out-of-pocket expenses related to NCC. RESULTS: The annual average per-patient direct costs were US$ 503 (95% CI: 414-592) and US$ 438 (95% CI: 322-571) for patients without a history of hospitalisation and/or surgery seen at the INNN and the HE-IMSS, respectively. These costs increased to US$ 2506 (95% CI: 1797-3215) and US$ 2170 (95% CI: 1303-3037), respectively, for patients with a history of hospitalisation and/or surgery. The average annual per-patient indirect costs were US$ 246 (95% CI: 165-324) and US$ 114 (95% CI: 51-178), respectively, using minimum salary wages for individuals not officially employed. CONCLUSIONS: The total annual cost for patients who had and had not been hospitalised and/or undergone a surgical procedure for the diagnosis or treatment of NCC corresponded to 212% and 41% of an annual minimum wage salary, respectively. The disease tends to affect rural socioeconomically disadvantaged populations and creates health disparities and significant economic losses in Mexico.
OBJECTIVES: To estimate annual costs related to the diagnosis, treatment and productivity losses among patients with neurocysticercosis (NCC) receiving treatment at two referral hospitals, the Instituto Nacional de Neurologia y Neurocirugia (INNN) and the Hospital de Especialidades of the Instituto Mexicano del Seguro Social (HE-IMSS), in Mexico City from July 2007 to August 2008. METHODS: Information on presenting clinical manifestations, diagnostic tests, hospitalisations, surgical procedures and other treatments received by NCC outpatients was collected from medical charts, and supplemented by an individual questionnaire regarding productivity losses and out-of-pocket expenses related to NCC. RESULTS: The annual average per-patient direct costs were US$ 503 (95% CI: 414-592) and US$ 438 (95% CI: 322-571) for patients without a history of hospitalisation and/or surgery seen at the INNN and the HE-IMSS, respectively. These costs increased to US$ 2506 (95% CI: 1797-3215) and US$ 2170 (95% CI: 1303-3037), respectively, for patients with a history of hospitalisation and/or surgery. The average annual per-patient indirect costs were US$ 246 (95% CI: 165-324) and US$ 114 (95% CI: 51-178), respectively, using minimum salary wages for individuals not officially employed. CONCLUSIONS: The total annual cost for patients who had and had not been hospitalised and/or undergone a surgical procedure for the diagnosis or treatment of NCC corresponded to 212% and 41% of an annual minimum wage salary, respectively. The disease tends to affect rural socioeconomically disadvantaged populations and creates health disparities and significant economic losses in Mexico.
Authors: Alfonso J Rodríguez-Morales; María Camila Yepes-Echeverri; Wilmer F Acevedo-Mendoza; Hamilton A Marín-Rincón; Carlos Culquichicón; Esteban Parra-Valencia; Jaime A Cardona-Ospina; Ana Flisser Journal: Travel Med Infect Dis Date: 2017-12-27 Impact factor: 6.211
Authors: Dinh Ng-Nguyen; Mark A Stevenson; Pierre Dorny; Sarah Gabriël; Tinh Van Vo; Van-Anh Thi Nguyen; Trong Van Phan; Sze Fui Hii; Rebecca J Traub Journal: PLoS Negl Trop Dis Date: 2017-07-07
Authors: Rachana Bhattarai; Hélène Carabin; Jose Flores-Rivera; Teresa Corona; Jefferson V Proaño; Ana Flisser; Christine M Budke Journal: Rev Inst Med Trop Sao Paulo Date: 2018-05-28 Impact factor: 1.846
Authors: Rachana Bhattarai; Hélène Carabin; Jefferson V Proaño; Jose Flores-Rivera; Teresa Corona; Ana Flisser; Leith León-Maldonado; Christine M Budke Journal: PLoS Negl Trop Dis Date: 2019-07-10